Hope S. Rugo, MD, MBA, and Paolo Tarantino, MD, give a preview to a first-of-its-kind Tweet Chat taking place in January 2023.
Atezolizumab/Chemo Combo Yields Survival Benefit in Metastatic TNBC
December 21st 2023Lower risk of disease progression following treatment with atezolizumab and carboplatin for metastatic triple-negative breast cancer appears to be associated with increases in tumor infiltrating lymphocytes and tumor mutational burden.
Pembrolizumab Combo Does Not Improve PFS/OS in Advanced/Metastatic TNBC
December 7th 2023Data from the phase 2 KEYLYNK-009 study indicate a lower rate of treatment-related adverse effects with pembrolizumab plus olaparib compared with pembrolizumab plus chemotherapy in those with triple-negative breast cancer.